{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:11:12Z","timestamp":1788923472172,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T00:00:00Z","timestamp":1676851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Candidemia is increasing in frequency and is associated with high mortality. We sought to determine the burden of illness, the population it affects and its resistance profile in our region.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The Calgary Zone (CZ) provides all care for residents of Calgary and surrounding communities (~\u20091.69 million) via five tertiary hospitals each served by a common single laboratory for acute care microbiology. All adult patients in the CZ with at least one\n                      <jats:italic>Candida<\/jats:italic>\n                      spp.-positive blood culture between January 1, 2010, and December 31, 2018, were identified using microbiological data from Calgary Lab Services, the laboratory that processes\u2009&gt;\u200995% of all blood culture samples in the CZ, were reviewed for the study.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall annual incidence of candidemia among individuals living in the CZ was 3.8 per 100,000 persons (Median age 61\u00a0years (IQR 48\u201372) and 221\/455 (47.4%) were female).\n                      <jats:italic>C. albicans<\/jats:italic>\n                      was the most common species (50.6%), followed by\n                      <jats:italic>C. glabrata,<\/jats:italic>\n                      (24.0%). No other species accounted for more than 7% of cases. Overall mortality at 30, 90, and 365\u00a0days was 32.2, 40.1, and 48.1% respectively. Mortality rate did not differ by\n                      <jats:italic>Candida<\/jats:italic>\n                      species. Of individuals who developed candidemia, more than 50% died within the next year. No new resistance pattern has emerged in the most common\n                      <jats:italic>Candida<\/jats:italic>\n                      species in Calgary, Alberta.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      In Calgary, Alberta, the incidence of candidemia has not increased in the last decade.\n                      <jats:italic>C. albicans<\/jats:italic>\n                      was the most common species and it remains susceptible to fluconazole.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08050-0","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:03:23Z","timestamp":1676876603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010\u20132018)"],"prefix":"10.1186","volume":"23","author":[{"given":"Samuel","family":"Bourassa-Blanchette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marit M.","family":"Biesheuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Kipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deirdre","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Dalton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Parkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman W.","family":"Barkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Gregson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,20]]},"reference":[{"key":"8050_CR1","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1086\/496922","volume":"41","author":"TE Zaoutis","year":"2005","unstructured":"Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232\u20139.","journal-title":"Clin Infect Dis"},{"key":"8050_CR2","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1128\/JCM.39.9.3254-3259.2001","volume":"39","author":"MA Pfaller","year":"2001","unstructured":"Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surv. J Clin Microbiol. 2001;39:3254\u20139.","journal-title":"J Clin Microbiol"},{"key":"8050_CR3","doi-asserted-by":"crossref","unstructured":"Tsay SV, Mu Y, Williams S, Epson E, Nadle J, Bamberg WM, et al. Burden of Candidemia in the United States, 2017. Clin Infect Dis. 2020;e449\u2013e453.","DOI":"10.1093\/cid\/ciaa193"},{"key":"8050_CR4","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/jac\/dki258","volume":"56","author":"KB Laupland","year":"2005","unstructured":"Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother. 2005;56:532\u20137.","journal-title":"J Antimicrob Chemother"},{"key":"8050_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0097325","volume":"9","author":"DE Corzo-Leon","year":"2014","unstructured":"Corzo-Leon DE, Alvarado-Matute T, Colombo AL, Cornejo-Juarez P, Cortes J, Echevarria JI, et al. Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals. PLoS ONE. 2014;9: e97325.","journal-title":"PLoS ONE"},{"key":"8050_CR6","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1155\/2013\/929717","volume":"24","author":"GN Al-Rawahi","year":"2013","unstructured":"Al-Rawahi GN, Roscoe DL. Ten-year review of candidemia in a Canadian tertiary care centre: predominance of non-albicans Candida species. Can J Infect Dis Med Microbiol. 2013;24:e65\u20138.","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"8050_CR7","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13655","volume":"75","author":"NS Raja","year":"2021","unstructured":"Raja NS. Epidemiology, risk factors, treatment and outcome of Candida bloodstream infections because of Candida albicans and Candida non-albicans in two district general hospitals in the United Kingdom. Int J Clin Pract. 2021;75: e13655.","journal-title":"Int J Clin Pract"},{"key":"8050_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1046\/j.1439-0507.2002.00741.x","volume":"45","author":"GLP MacPhail","year":"2002","unstructured":"MacPhail GLP, Taylor GD, Buchanan-Chell M, Ross C, Wilson S, Kureishi A. Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses. 2002;45:141\u20135.","journal-title":"Mycoses"},{"key":"8050_CR9","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1093\/cid\/ciy776","volume":"68","author":"K Benedict","year":"2019","unstructured":"Benedict K, Jackson BR, Chiller T, Beer KD. Estimation of direct healthcare costs of fungal diseases in the United States. Clin Infect Dis. 2019;68:1791\u20137.","journal-title":"Clin Infect Dis"},{"key":"8050_CR10","doi-asserted-by":"crossref","unstructured":"Spivak ES, Hanson KE. Candida auris: an emerging fungal pathogen. J Clin Microbiol. 2018;56.","DOI":"10.1128\/JCM.01588-17"},{"key":"8050_CR11","doi-asserted-by":"publisher","first-page":"606976","DOI":"10.3389\/fmed.2020.606976","volume":"7","author":"EJ Kim","year":"2020","unstructured":"Kim EJ, Lee E, Kwak YG, Yoo HM, Choi JY, Kim SR, et al. Trends in the epidemiology of candidemia in intensive care units from 2006 to 2017: results from the Korean National Healthcare-Associated Infections Surveillance System. Front Med (Lausanne). 2020;7:606976\u2013606976.","journal-title":"Front Med (Lausanne)"},{"key":"8050_CR12","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1086\/599039","volume":"48","author":"DL Horn","year":"2009","unstructured":"Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes of Candidemia in 2019 patients: data from the Prospective Antifungal Therapy Alliance Registry. Clin Infect Dis. 2009;48:1695\u2013703.","journal-title":"Clin Infect Dis"},{"key":"8050_CR13","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.diagmicrobio.2012.02.020","volume":"73","author":"EL Ericson","year":"2012","unstructured":"Ericson EL, Klingspor L, Ullberg M, \u00d6zenci V. Clinical comparison of the Bactec Mycosis IC\/F, BacT\/Alert FA, and BacT\/Alert FN blood culture vials for the detection of candidemia. Diagn Microbiol Infect Dis. 2012;73:153\u20136.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"8050_CR14","doi-asserted-by":"publisher","DOI":"10.1128\/9781555817435","volume-title":"Clinical microbiology procedures handbook","author":"LS Garcia","year":"2010","unstructured":"Garcia LS. Clinical microbiology procedures handbook. 3rd ed. Washington, D.C: ASM Press; 2010.","edition":"3"},{"key":"8050_CR15","volume-title":"Clinical microbiology procedures handbook","author":"AL Leber","year":"2016","unstructured":"Leber AL. Clinical microbiology procedures handbook. 4th ed. Washington, DC: ASM Press; 2016.","edition":"4"},{"key":"8050_CR16","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1128\/JCM.00937-12","volume":"50","author":"MA Pfaller","year":"2012","unstructured":"Pfaller MA, Diekema DJ. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J Clin Microbiol. 2012;50:2846\u201356.","journal-title":"J Clin Microbiol"},{"key":"8050_CR17","unstructured":"CLSI. Epidemiological cutoff values for antifungal susceptibility testing, 3rd edn. Clinical and Laboratory Standards Institute. 2020."},{"key":"8050_CR18","unstructured":"CLSI. Performance standards for antifungal susceptibility testing of yeasts, 2nd edn. Clinical and Laboratory Standards Institute. 2020."},{"key":"8050_CR19","unstructured":"Calgary\u2014Population. 2022. https:\/\/regionaldashboard.alberta.ca\/region\/calgary\/population\/#\/?from=2001&to=2019. Accessed 28 Aug 2022."},{"key":"8050_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.idc.2021.03.007","volume":"35","author":"TP McCarty","year":"2021","unstructured":"McCarty TP, White CM, Pappas PG. Candidemia and invasive Candidiasis. Infect Dis Clin N Am. 2021;35:389\u2013413.","journal-title":"Infect Dis Clin N Am"},{"key":"8050_CR21","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1111\/j.1469-0691.2010.03338.x","volume":"17","author":"P Mu\u00f1oz","year":"2011","unstructured":"Mu\u00f1oz P, Giannella M, Fanciulli C, Guinea J, Valerio M, Rojas L, et al. Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. Clin Microbiol Infect. 2011;17:1538\u201345.","journal-title":"Clin Microbiol Infect"},{"key":"8050_CR22","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","volume":"379","author":"SS Magill","year":"2018","unstructured":"Magill SS, O\u2019Leary E, Janelle SJ, Thompson DL, Dumyati G, Nadle J, et al. Changes in prevalence of health care-associated infections in US hospitals. N Engl J Med. 2018;379:1732\u201344.","journal-title":"N Engl J Med"},{"key":"8050_CR23","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","volume":"25","author":"P Koehler","year":"2019","unstructured":"Koehler P, Stecher M, Cornely OA, Koehler D, Vehreschild MJGT, Bohlius J, et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect. 2019;25:1200\u201312.","journal-title":"Clin Microbiol Infect"},{"issue":"suppl1","key":"8050_CR24","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.1093\/ofid\/ofy210.374","volume":"5","author":"S Tsay","year":"2018","unstructured":"Tsay S, Williams S, Mu Y, Epson E, Johnston H, Farley MM, et al. 363. National Burden of Candidemia, United States, 2017. Open Forum Infect Dis. 2018;5(suppl1):S142\u20133.","journal-title":"Open Forum Infect Dis"},{"key":"8050_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/1469-0691.12539","volume":"20","author":"J Guinea","year":"2014","unstructured":"Guinea J. Global trends in the distribution of Candida species causing candidemia. Clin Microbiol Infect. 2014;20:5\u201310.","journal-title":"Clin Microbiol Infect"},{"key":"8050_CR26","doi-asserted-by":"publisher","first-page":"ofac545","DOI":"10.1093\/ofid\/ofac545","volume":"9","author":"EE Seagle","year":"2022","unstructured":"Seagle EE, Jackson BR, Lockhart SR, Jenkins EN, Revis A, Farley MM, et al. Recurrent Candidemia: trends and risk factors among persons residing in 4 US States, 2011\u20132018. Open Forum Infect Dis. 2022;9:ofac545.","journal-title":"Open Forum Infect Dis"},{"key":"8050_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1128\/JCM.02481-13","volume":"52","author":"MA Pfaller","year":"2014","unstructured":"Pfaller MA, Messer SA, Diekema DJ, Jones RN, Castanheira M. Use of Micafungin as a surrogate marker to predict susceptibility and resistance to Caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria. J Clin Microbiol. 2014;52:108.","journal-title":"J Clin Microbiol"},{"key":"8050_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jinf.2015.05.009","volume":"71","author":"M Fern\u00e1ndez-Ruiz","year":"2015","unstructured":"Fern\u00e1ndez-Ruiz M, Puig-Asensio M, Guinea J, Almirante B, Padilla B, Almela M, et al. Candida tropicalis bloodstream infection: incidence, risk factors and outcome in a population-based surveillance. J Infect. 2015;71:385\u201394.","journal-title":"J Infect"},{"key":"8050_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13756-021-00890-2","volume":"10","author":"D Wang","year":"2021","unstructured":"Wang D, An N, Yang Y, Yang X, Fan Y, Feng J. Candida tropicalis distribution and drug resistance is correlated with ERG11 and UPC2 expression. Antimicrob Resist Infect Control. 2021;10:54.","journal-title":"Antimicrob Resist Infect Control"},{"key":"8050_CR30","doi-asserted-by":"crossref","unstructured":"Kim EJ, Lee E, Kwak YG, Yoo HM, Choi JY, Kim SR, et al. Trends in the epidemiology of Candidemia in intensive care units from 2006 to 2017: results from the Korean National Healthcare-Associated Infections Surveillance System. Front Med (Lausanne). 2020;7.","DOI":"10.3389\/fmed.2020.606976"},{"key":"8050_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6808a1","volume":"68","author":"M Toda","year":"2019","unstructured":"Toda M, Williams SR, Berkow EL, Farley MM, Harrison LH, Bonner L, et al. Population-based active surveillance for culture-confirmed Candidemia\u2014four sites, United States, 2012\u20132016. MMWR Surveill Summ. 2019;68:1\u201317.","journal-title":"MMWR Surveill Summ"},{"key":"8050_CR32","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/mmy\/myy118","volume":"57","author":"G Cuervo","year":"2019","unstructured":"Cuervo G, Garcia-Vidal C, Puig-Asensio M, Merino P, Vena A, Mart\u00edn-Pe\u00f1a A, et al. Usefulness of guideline recommendations for prognosis in patients with candidemia. Med Mycol. 2019;57:659\u201367.","journal-title":"Med Mycol"},{"key":"8050_CR33","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of Candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50.","journal-title":"Clin Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08050-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08050-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T07:04:05Z","timestamp":1676876645000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08050-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,20]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8050"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08050-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2105877\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,20]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Conjoint Health Research Ethics Board approved the study protocols (REB18-1659). All methods were performed in accordance with relevant guidelines and regulations. The Conjoint Health Research Ethics Board approved the study with a waiver for informed consent (REB18-1659).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm there are no competing interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}